Kairos Pharma, Ltd. (KAPA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Kairos Pharma, Ltd. on October 7, 2025, covering events occurring on October 1, 2025, and October 7, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Los Angeles, California. The filing primarily addresses the consolidation of intellectual property rights from its subsidiary, EnviroTherapeutics, Inc. ("Enviro"), and an upcoming clinical data presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on material agreements and corporate events rather than financial performance metrics.
Material Changes and Agreements
- Cedars-Sinai Novation Agreement: On October 1, 2025, the Board approved a novation agreement with Cedars-Sinai Medical Center, effective April 17, 2025. This agreement transfers the exclusive license of two patents from Enviro to Kairos. Kairos assumed all obligations and liabilities, relieving Enviro of them. The patents cover:
- Compositions and methods for treating diseases by depletion of mitochondrial or genomic DNA from circulation.
- Sensitization of tumors to therapies through endoglin antagonism.
- Tracon Novation Agreement: On October 1, 2025, the Board approved a novation agreement with Tracon Pharmaceuticals, Inc. and Enviro. This transfers Enviro's rights and obligations under the existing license and supply agreement (originally dated May 21, 2021) to Kairos. Kairos now holds exclusive access to Tracon's TRC105 and CD105 technologies.
Outlook, Events, and Risks
- Clinical Presentation: On October 7, 2025, Kairos announced its selection to present at the European Society for Medical Oncology Congress in Berlin, Germany (October 7–21, 2025). The presentation will cover preliminary safety and clinical activity from a Phase 2 study of apalutamide + carotuximab in advanced, castration-resistant prostate cancer.
- Legal Disclaimer: Information regarding the clinical presentation (Item 8.01) is furnished and not deemed "filed" under the Exchange Act, nor is it incorporated by reference into other filings.
Investor Verification Checklist
- Verify the full text of the Cedars-Sinai and Tracon Novation Agreements (Exhibits 10.1 and 10.2) to understand specific financial obligations or milestones assumed by Kairos.
- Confirm the status of the Phase 2 study for apalutamide + carotuximab and the timing of the full data release following the ESMO Congress presentation.
- Review the Company's latest 10-K or 10-Q filings for current cash runway and liquidity status, as this 8-K does not contain financial data.
- Monitor the impact of consolidating Enviro's IP on the Company's overall valuation and potential future licensing revenue.